Cervical cancer and CYP2E1 polymorphisms: Implications for molecular epidemiology

European Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 15-21

  Ferreira, Paula M ^a   Catarino, Raquel ^a   Pereira, Deolinda ^a   Matos, Ana ^a,b   Pinto, Daniela ^a   Coelho, Ana ^a   Lopes, Carlos ^a   Medeiros, Rui ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Matern Julio Dinis   (Portugal)

Author keywords

Cervical cancer; CYP2E1; Inflammation; Polymorphisms

Indexed keywords

CYTOCHROME P450 2E1; PROTEIN; PROTEIN DRA1; PROTEIN RSA1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER GENETICS; CANCER INVASION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR EPIDEMIOLOGY; POLYMERASE CHAIN REACTION; PORTUGAL; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STRATIFICATION; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGE FACTORS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOCHROME P-450 CYP2E1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PORTUGAL; UTERINE CERVICAL NEOPLASMS;

EID: 30844456881     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0066-y     Document Type: Article

References (59)

1. Parkin DM, Pisani P, Ferlay J (1990) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827-841
2. Pinheiro PS, Tyczynski JE, Bray F, Amado J, Matos E, Parkin DM (2003) Cancer incidence and mortality in Portugal. Eur J Cancer 39:2507-2520
3. Franco EL, Rohan TE, Villa LL (1999) Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91:506-511
4. Bosch FX, Lorincz A, Munoz NN, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265
5. Castle PE, Giuliano AR (2003) Genital tract infections, cervical inflammation, and antioxidant nutrients - assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 31:29-34
6. Haverkos H, Rohrer M, Pickworth W (2000) The cause of invasive cervical cancer could be multifactorial. Biomed Pharmacother 54:54-59
7. Kjellberg L, Halmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T, Dillner J (2000) Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intraepithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82:1332-1338
8. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, de Sanjose S, Munoz N, IARC Multi-centre Cervical Cancer Study Group (2003) Smoking and cervical cancer: pooled analysis of the LARC multi-centric case-control study. Cancer Causes Control 14:805-814
9. Prokopczyk B, Cox JE, Hoffmann D, Waggoner S (1997) Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 89:868-873
10. Melikian AA, Sun P, Prokopczyk B, El-Bayoumy K, Hoffmann D, Wang X, Waggoner S (1999) Identification of benzo[a] pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Lett 146:127-134
11. Castellsague X, Bosch FX, Munoz N (2002) Environmental cofactors in HPV carcinogenesis. Virus Res 89:191-199
12. Bayo S, Bosch FX, de Sanjosé S, Munoz N, Combita AL, Coursaget P, Diaz M, Dolo A, van den Brule AJ, Meijer CJ (2002) Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 31:202-209
13. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX, IARC Multicentric Cervical Cancer Study Group (2002) Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359:1093-1101
14. Thomas DB, Qin Q, Kuypers J, Kiviat N, Ashley RL, Koetsawang A, Ashley RL, Qin Q, Koetsawang S (2001) Human papillomavirus and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. Am J Epidemiol 153:732-739
15. Hernandez BY, McDuffie K, Wilkens LR, Kamemoto L, Goodman MT (2003) Diet and premalignant lesions of the cervix: evidence of a protective role for folate, riboflavin, thiamine and vitamin B12. Cancer Causes Control 14:859-870
16. Murthy NS, Mathew A (2000) Risk factors for pre-cancerous lesions of the cervix. Eur J Cancer Prev 9:5-14
17. Guengerich FP, Kim DH, Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low-molecular-weight cancer suspects. Chem Res Toxicol 4:168-719
18. Yamazaki H, Inui Y, Yun CH (1992) Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-dialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789-1794
19. Liber CS (1997) Cytochrome P-4502E1: its physiological and pathological role. Physiol Ver 77:517-544
20. Weiderpass E, Ye W, Tamimi R, Trichopolous D, Nyren O, Vainio H, Adami HO (2001) Alcoholism and risk for cancer of the cervix uteri, vagina, and vulva. Cancer Epidemiol Biomarkers Prev 10:899-901
21. Uematsu F, Kikuchi H, Motmyia M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M (1991) Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82:254-256
22. Uematsu F, Kikuchi H, Ohmachi T, Sagami I, Motomyia M, Kamataki T, Komori M, Watanabe M (1991) Two common RFLPs of CYP2E gene. Nucleic Acids Res 19:2803
23. Watanabe J, Hayashi SI, Nakachi K, Imai K, Suda Y, Sekine T, Kawajiri K (1990) PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E1 gene. Nucleic Acids Res 18:7194
24. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9:3-28
25. Agundez JA (2004) Cytochrome P450 polymorphism and cancer. Curr Drug Metab 5:211-224
26. Hirvonen A, Husgafvel-Pursiainen K, Antila S, Karjalainen A, Vainio H (1993) The human CYP2E1 gene and ling cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14:85-88
27. Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R, Abe T, Satoh K, Motomyia M, Watanabe M (1994) Restriction fragment length polymorphism of human CYP2E1 (cytochrome P450IIE1) gene and the susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 4:58-63
28. Hildsheim A, Anderson LM, Chen CJ, Cheng YJ, Brinton LA, Daly AK, Reed CD, Chen IH, Caporaso NE, Hsu MM, Chen JY, Idle JR, Hoover RN, Yang CS, Chhabra SK (1997) CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 89:1207-1212
29. Bouchardy C, Hirvonen A, Coutelle C, Ward PJ, Dayer P, Benhamou S (2000) Role of dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the aerodigestive tract. Int J Cancer 87:734-740
30. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shiraishi T (2001) Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 165:171-177
31. Ferreira PM, Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, Lopes C (2003) Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. Eur J Cancer Prev 12:205-211
32. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE (2000) Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1 and CYP2E1. Cancer 88:2082-2091
33. Sierra-Torres CH, Au WW, Arrastia CD, Cajas-Salazar N, Rabazetti SC, Payne DA, Tyring SK (2003) Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen 41:69-76
34. Costa S, Medeiros R, Vasconcelos A, Pinto D, Lopes C (2002) A slow acetylator genotype associated with an increased risk of advanced cervical cancer. J Cancer Res Clin Oncol 128:678-682
35. Craveiro R, Costa S, Pinto D, Salgado L, Carvalho L, Castro C, Bravo I, Lopes C, Silva I, Medeiros R (2004) TP73 alterations in cervical carcinoma. Cancer Genet Cytogenet 150:116-121
36. Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, Lopes C, Medeiros R (2005) Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 160:49-54
37. Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes, Medeiros R (2005) Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol 96:760-764
38. Müllenbach R, Lagoda PJ, Welter C (1989) An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 5:391
39. Kato S, Onda M, Matsukura N, Tokunaga A, Matsuda N, Yamashita K, Shields PG (1996) Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. Cancer 77:1654-1661
40. Farin FM, Bigler LG, Oda D, McDougall JK, Omiecinski CJ (1995) Expression of cytochrome P450 and microsomal epoxide hydrolase in cervical and oral epithelial cells immortalized by human papillomavirus type 16 E6/E7 genes. Carcinogenesis 16:1391-1401
41. Castle PE, Hillier SL, Rabe LK, Hildsheim A, Herrero R, Bratti MC, Sherman ME, Burk RD, Rodriguez AC, Alfaro M, Hutchinson ML, Morales J, Schiffman M (2001) An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10:1021-1027
42. Tindle RW (2001) Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev Cancer 2:1-7
43. Herrero R, Brinton LA, Reeves WC, Brenes MM, Tenorio F, de Britton RC, Gaitan E, Garcia M, Rawls WE (1990) Sexual behavior, venereal diseases, hygiene practices and invasive cervical cancer in a high-risk population. Cancer 65:380-386
44. Bachmann A, Hanke B, Zawatzky R, Soto U, van Riggelen J, zur Hausen H, Rosl F (2002) Disturbance of tumor necrosis factor alpha-mediated beta interferon signalling in cervical carcinoma cells. J Virol 76:280-291
45. Pao CC, Lin CY, Yao DS, Tseng CJ (1995) Differential expression of cytokine genes in cervical cancer tissues. Biochem Biophys Res Commun 214:1146-1151
46. de Gruijl TD, Bontkes HJ, van der Muysenberg AJ, van Oostveen JW, Stukart MJ, Verheijen RH, van der Vange N, Snijders PJ, Meijer CJ, Walboomers JM, Scheper RJ (1999) Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer 35:490-497
47. Hagari Y, Budgeon LR, Pickel MD, Kreider JW (1995) Association of tumor necrosis factor alfa gene expression and apoptotic cell death with regression of Shope papillomas. J Investig Dermatol 104:526-529
48. Hakkola J, Hu Y, Ingelman-Sundberg M (2003) Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J Pharmacol Exp Ther 304:1048-1054
49. Woodworm CD (2002) HPV innate immunity. Front Biosci 7:d2058-2071
50. Morgan ET (2001) Regulation of cytochrome p450 by inflammatory mediators: why and how. Drug Metab Dispos 29:207-212
51. Qiu LO, Linder MW, Antonino-Green DM, Valdes Jr R (2004) Suppression of cytochrome P450 2E1 promoter activity by interferon gamma and loss of response due to the -71G>T nucleotide polymorphism of the CYP2E1*B allele. J Pharmacol Exp Ther 308:284-288
52. d'Errico A, Malats N, Vineis P, Boffetta P (1999) Review of studies of selected metabolic polymorphisms and cancer. IARC Scientific Publication No. 148. IARC, Lyon, pp 323-393
53. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300-310
54. Bolt HM, Roos PH, Their R (2003) The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 76:174-185
55. Raunnio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A (1995) Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review. Gene 159:113-121
56. Quinones L, Berthou F, Varela N, Simon B, Gil L, Lucas D (1999) Ethnic susceptibility to lung cancer: differences in CYP2E1, CYP1A1 and GSTM1 genetic polymorphisms between French Caucasian and Chilean populations. Cancer Lett 141:167-171
57. Martínez C, Agúndez JA, Olivera M, LLerena A, Ramirez R, Hernández M, Benítez J (1998) Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analysis of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population. Clin Pharmacol Ther 63:623-628
58. Persson I, Johanson I, Bergling H, Dahl M-L, Seidegard J, Rylander R, Rannug A, Hogberg J, Ingelman-Sundberg M (1993) Genetic polymorphisms of cytochrome P4502E1 in a Swedish population: relationship to incidence of lung cancer. FEBS Lett 319:207-211
59. Farker K, Lehmann MH, Kastner R, Hoffmann A, Janitzky V, Schubert J, Matz U, Hoffmann W (1998) CYP2E1 genotyping in renal cell/urothelial cancer patients in comparison with control populations. Int J Pharmcol Ther 36:463-468